ICER finds Lemtrada most cost-effective in MS

In an evidence report evaluating disease-modifying therapies for multiple sclerosis, the Institute for Clinical and Economic Review said Lemtrada alemtuzumab from Sanofi (Euronext:SAN; NYSE:SNY) "consistently demonstrated improved health outcomes and good value" at a lower cost

Read the full 367 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE